Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leriglitazone - Minoryx Therapeutics

Next Previous
Drug Profile

Leriglitazone - Minoryx Therapeutics

Alternative Names: Leriglitazone hydrochloride; MIN-102; NEZGLYAL

Latest Information Update: 27 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IDIBELL
  • Developer Minoryx Therapeutics
  • Class Neuroprotectants; Phenyl ethers; Pyridines; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy; Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Adrenoleucodystrophy
  • Phase II Friedreich's ataxia; Rett syndrome
  • No development reported CNS disorders

Most Recent Events

  • 06 Mar 2025 Minoryx Therapeutics completes the phase II/III ADVANCE trial for Adrenoleucodystrophy in Spain, Netherlands, Hungary, France, Germany, Italy, United Kingdom, and USA (PO) (NCT03231878)
  • 04 Mar 2025 Phase-II clinical trials in Rett syndrome (In children) in Spain (PO) prior to March 2025
  • 04 Mar 2025 Preclinical trials in Rett syndrome in Spain (PO) prior to March 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top